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Abstract 
Objective:  As multiple genes with small effect size are assumed to play a role in attention-
deficit/hyperactivity disorder (ADHD) disease etiology, considering multiple variants within the same 
analysis likely increases the total explained phenotypic variance, thereby boosting the power of 
genetic studies. We investigated whether pathway-based analysis could bring us closer to unraveling 
the biology of ADHD.  
Method: We describe pathway as a pre-defined gene selection based on a well-established database 
or literature data. Common genetic variants in pathways involved in dopamine/noradrenaline and 
serotonin neurotransmission and genes involved in neurite outgrowth were investigated in cases from 
the International Multicentre ADHD Genetics (IMAGE) study. We performed multivariable analysis to 
combine the effects of single genetic variants within the pathway genes. Phenotypes were DSM-IV 
symptom counts for inattention and hyperactivity/impulsivity (n=871) and symptom severity measured 
with the Conners Parent (n=930) and Teacher Rating Scales (n=916).  
Results: Summing genetic effects of common genetic variants within the pathways showed significant 
association with hyperactive/impulsive (pempirical=0.007), but not inattentive symptoms (pempirical=0.73). 
Analysis of parent-rated Conners hyperactive/impulsive symptom scores validated this result 
(pempirical=0.0018). Teacher-rated Conners scores were not associated. Post-hoc analyses showed 
significant contribution of all pathways to the hyperactive/impulsive symptom domain 
(dopamine/noradrenaline pempirical=0.0004, serotonin pempirical=0.0149, neurite outgrowth 
pempirical=0.0452).  
Conclusion: The current analysis shows association between common  variants in three genetic 
pathways with the hyperactive/impulsive component of ADHD.  This study demonstrates that pathway-
based association analyses, using quantitative measures of ADHD symptom domains may increase 
the power of genetic analyses to identify biological risk factors involved in this disease. 
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Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder characterized 
by developmentally inappropriate inattentiveness and/or increased impulsivity and hyperactivity
1
. 
Although ADHD is highly heritable, with heritability estimates around 76%
2
, discovering genetic risk 
variants has been challenging. A number of candidate genes have been associated, but altogether 
explain only a small part of the heritability
3
, and so far, genome-wide association studies (GWASs) 
have not yielded genome-wide significant findings
4
.   
Difficulty in discovering genetic risk variants has been attributed to the fact that ADHD is clinically 
heterogeneous
5
. Factor analyses of ADHD symptoms demonstrate that ADHD is indeed 
multidimensional, with studies of teacher and parent ratings supporting a two-factor structure in 
children
6
 separating inattention and  hyperactivity/impulsivity. The Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) diagnostic criteria make sub-classifications, distinguishing an inattentive 
clinical subtype (predominantly inattentive symptoms), a hyperactive/impulsive subtype (predominantly 
hyperactive/impulsive symptoms) and a combined type ADHD (both inattentive symptoms as well as 
hyperactive/impulsive symptoms)
1
. The two symptom domains of ADHD can be attributed, in part, to 
different brain networks
7
 and twin studies show partial genetic overlap between inattentive and 
hyperactive/impulsive symptoms, but also clear genetic specificity
8
. For these reasons, studying the 
genetics of symptom domains separately might reduce phenotypic heterogeneity, increase the power 
of genetic studies, and enable us to identify dimension-specific genetic risk variants.   
Apart from the multidimensionality, additional challenges in discovering genetic risk variants in ADHD 
are the small effect sizes of single common genetic variants and different genetic variants leading to 
similar phenotypes
9
. As genome-wide genetic analyses aimed at identifying common risk variants, 
mainly focused on investigating Single Nucleotide Polymorphisims (SNPs)
10-12
 association, extremely 
large samples are needed to achieve genome-wide significance
4,13
 and sample sizes in ADHD 
research are still small compared to other disorders
13
. A recent study performing cross-disorder 
GWAS using data from the Psychiatric Genomics Consortium of cases and controls for schizophrenia, 
bipolar disorder, major depressive disorder, autism spectrum disorders and ADHD, showed a 
significant polygenic component for ADHD, suggesting that searching for a combination of genetic 
variants might be fruitful
14
. Considering the combined effect of multiple variants in the same analysis 
3 
 
might increase the explained phenotypic variance
15
, thereby boosting the power of genetic studies. 
Therefore, we investigated whether pathway-based analyses considering multiple SNPs within the 
same biological process, could bring us closer to unraveling the underlying genetic component of 
ADHD.  
Alterations in dopaminergic, noradrenergic and serotonergic neurotransmission have been 
hypothesized to play a role in ADHD
16,17
. Medications used to treat ADHD affect these systems
18,19
 
and reduce behavioral symptoms
20,21
.  Although serotonergic medications are not efficacious for 
ADHD
22
, serotonin interacts with dopamine
23
, therefore medication working on the dopamine system 
might also alter serotonin signaling. Secondly, projection sites of these neurotransmitter systems 
regulate cognitive processes, attention and motor behavior in ADHD, supported by structural and 
functional imaging data
24-26
. Thirdly, although not achieving genome-wide significance, genetic 
associations have been found for several candidate genes within these systems
3
. Finally, animal 
studies show gene knock-out of catecholaminergic genes to cause ADHD-like behavior, altered 
catecholamine release and symptom reduction in response to ADHD medication
27
. In addition, another 
biological process implicated in ADHD, mainly through genetic studies, is neurite outgrowth
9
. Genes 
involved in this process were found to be enriched in the top results of the five available GWASs of 
ADHD
28
.  
Prior studies investigated whether SNPs in the top results of individual analysis were overrepresented 
in pre-determined gene/pathways lists , or if those genes formed a network of functionally interacting 
proteins
29
. Others selected variants based on candidate genes/pathways from literature
30
. However, 
so far no studies have conducted a combined analysis of candidate genetic pathways allowing to 
investigate if certain genetic pathways together are associated with disorder-specific phenotypes.  
In the current study we used a case-only design to investigate whether pathway-based analyses of 
dopamine, noradrenaline and serotonin neurotransmission and genes involved in neurite outgrowth 
moderate the underlying behavioral components and severity of ADHD. Common genetic variants 
within these pathways were included into the same analysis.     
 
Method 
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Sample 
The present study is part of the International Multicentre ADHD Genetics (IMAGE) study
31-33
, an 
international collaborative study in seven European countries (Belgium, Germany, Ireland, Spain, 
Switzerland, the Netherlands and the United Kingdom) and Israel aiming at identifying genes that 
increase ADHD susceptibility. Participants were aged 5–17 years and of European Caucasian 
descent, based on information on ethnicity and genetic data
34
(see Supplementary Figure S1). 
Exclusion criteria included IQ < 70, presence of autism, epilepsy, known neurological disorders and 
any genetic or medical disorder associated with externalizing behaviors that might mimic ADHD. 
Details of the sample have been described elsewhere
31,35
.   
 
ADHD phenotyping 
In short, a semistructured, standardized, investigator-based interview (Parental Account of Children’s 
symptoms [PACS]
36
) and questionnaires (parent and teacher Conners long version rating scales
37
, 
parent and teacher Strengths and Difficulties Questionnaires (SDQ)
38
) were used to establish an 
ADHD diagnosis in children previously clinically diagnosed with ADHD, see
39
 for the standardized 
algorithm that was applied to derive each of the 18 DSM-IV
1
 symptoms. Symptom count was defined 
by the number of symptoms per behavioral domain. Both symptom domains ranged from 0-9 
symptoms. To investigate symptom severity a 4-point scale was used from the inattention and 
hyperactivity/impulsivity subscales of the Conners Parent Rating Scale (CPRS-R)
40
 and the Conners 
Teacher Rating Scale (CTRS-R)
41
.  
 
Genotyping 
Genome-wide genotyping of the IMAGE probands was performed as part of the GAIN study using the 
Perlegen genotyping platform, described before
42
. To increase coverage, an imputation approach was 
used with the Hapmap II release 22 data set
43
. The imputed data underwent quality control in which 
SNPs with an imputation score < 0.3 and minor allele frequency < 0.05 were excluded. After this step 
we had 2,182,904 SNPs across the genome. To avoid overestimation of our statistics, linkage 
disequilibrium-pruned genotypes were used, using the “indep” command with an r
2
 threshold of 0.8 
(PLINK software
44
). After this step we had 299,296 SNPs. 
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In this work we describe pathway as a pre-defined gene selection based on a well-established genetic 
database or literature data. Selection of dopamine(74 genes) and serotonin(32 genes) genetic 
pathways was based on Ingenuity Pathway Analysis software (www.ingenuity.com). This is a well 
established, frequently updated genetic database for pathway analysis. The information used in 
Ingenuity to produce these pathways is extracted from the scientific literature, and includes genes, 
drugs, biomarkers, chemicals, cellular and disease processes, and signaling and metabolic pathways. 
For noradrenaline, only the receptors are defined in Ingenuity, no pathway has been defined yet. 
Noradrenaline and dopamine share most of their synthesis-pathway as noradrenaline arises from the 
hydroxylation of dopamine
45
. Promiscuity has been found for transporters
46
 and receptors
47,48
 of both 
noradrenalin and dopamine, probably due to the similarities in their chemical structure. By including 
the noradrenaline receptors(8 genes) and transporter with the dopamine pathway, we aimed at 
capturing the noradrenaline pathway as well. The dopamine/noradrenaline pathway contained 82 
genes. Dopamine/noradrenaline and serotonin pathways overlap in 13 genes. The selection of the 
neurite outgrowth genes was based on literature
28
, including 45 genes from the top results of the five 
GWAS studies available on ADHD. 
SNPs within all genes as well as 25 kilo basepairs (kb) flanking regions (capturing regulatory 
sequences) were selected. 
Data Analysis 
Association analysis to symptom counts was performed separately for hyperactive/impulsive 
symptoms and inattentive symptoms. Symptom count distribution were normalized and standardized 
using the Blom transformation (SPSS version 18).  
SNP-by-SNP linear regression was performed using the “linear” command in PLINK with sex and age 
as covariates. To decrease genetic heterogeneity, a combined analysis approach was applied using a 
multivariable approach described earlier
15
. By summing single SNP association statistics, the 
observed summed statistic was created. To get a distribution on permuted summed statistics we ran 
10,000 max(T) permutation tests using the “mperm” command, implemented in PLINK, for each SNP. 
The association statistics of the observed and permuted data were saved using the “mperm-save-all” 
PLINK command and added to create a summed statistic per run for all SNPs at the same time. The 
empirical p-value was determined as the number of times the observed summed statistic was smaller 
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than the permuted summed statistic divided by the total number of permutations. Significance 
threshold for the empirical p-values was set as 0.05 divided by the number of tests. 
We carried out our analysis in two steps. In step 1, we analyzed the combined effect of the SNPs in 
the three pathways on both inattentive and hyperactive/impulsive symptom counts . We then tested 
the association of the combined pathways with symptom severity using parental and teacher Conners 
scores. Post-hoc, we investigated potential effects of single pathways, genes and SNPs that might 
drive the association(Figure 1). Overlapping genes were only considered once in the combined 
analysis, but present in both separate analysis. For gene-wide association we used the analysis 
program VEGAS
49
. VEGAS uses single SNP p-values to perform gene-based association tests. 
Significance threshold was set to 0.05 divided by the number of genes tested. 
 
Results 
Table 1 shows the general characteristics of the studied sample.   
--Table 1-- 
Selection of dopamine/noradrenaline, serotonin and neurite outgrowth genes yielded a total of 146 
unique genes (Table 2). The dopamine/noradrenaline and the serotonin pathways overlapped in 13 
genes (251 SNPs). Four genes positioned on the X-chromosome (HTR2C, MAOA, MAOB and 
PPP2R3B) were not included in the analysis, one gene was not captured by the array used 
(PRKAR1B). The final data set contained 141 genes and 5,179 SNPs.  
--Table 2-- 
 
Step 1: The combined pathway analysis for DSM-IV symptom counts showed a significant association 
with hyperactive/impulsive symptoms (pempirical =0.007), but not with inattentive symptoms 
(pempirical=0.73) (Table 3). Single gene and single SNP analyses did not reveal significant associations  
Step 2: Given the results of step 1, we tested symptom severity of hyperactivity/impulsivity derived 
from the parental Conners scores with the three genetic pathways combined and observed a 
significant association (pempirical=0.0018). Post-hoc analyses showed that all pathways were 
independently associated with the hyperactivity/impulsivity score (dopamine/noradrenaline 
pempirical=0.0004, serotonin pempirical=0.0149, neurite outgrowth pempirical=0.0452) (Table 3). Single gene 
and single SNP analysis did not reveal significant associations. For further information on single SNP 
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results please contact the corresponding author directly. The combined pathways were not associated 
with hyperactive/impulsive scores on the teacher-rated Conners scale (pempirical=0.75).  
--Table 3— 
Table 4 shows a small to moderate correlation between hyperactive/impulsive and inattentive 
symptom counts. Hyperactive/impulsive symptom counts and Conners scores correlate moderately. 
--Table 4— 
 
Discussion 
The current study is the first to show an association between dopamine/noradrenaline, serotonin 
pathways and neurite outgrowth genes to the hyperactive/impulsive component of ADHD using 
hypothesis-based pathway association analysis using a case-only design. No association to the 
inattentive component was observed. Post-hoc analyses showed individual contribution of all three 
pathways. Single genes or SNPs did not show significant association, suggesting that the observed 
associations are the result of combined small effects of multiple genetic variants.  
The concept of biological pathways has been investigated before in ADHD. Top results from GWAS 
studies and rare variants were investigated for overrepresentation in certain genetic biological 
pathways
28,29
. Findings show overlap suggesting convergence of both rare and common variants in 
the risk of ADHD. When Elia et al.
50
 investigated rare variants only, they showed multiple genes 
carrying these variants belonging to the metabotropic glutamate receptor gene family. Another 
approach has been to use predefined genetic pathways as a starting point for gene/variant selection 
and testing
31,51-53
. Oades et al.
30
 selected genes that were related to serotonin function and applied a 
family-based multivariate approach clustering the phenotypes, to increase their statistical power. The 
current study extends previous approaches by including all variants in the studied pathways, by 
investigating both ADHD symptom domains separately, and by increasing our power by joining single 
SNP effects. Although IMAGE was part of these prior analysis (13 of the 45 neurite outgrowth genes 
were based on the single SNP effects in the IMAGE study), these 13 genes do not drive our results 
(see Supplementary Table S5).  
Our results suggest a link between candidate genetic pathways and hyperactivity/impulsivity but not 
with inattentiveness. Symptom domain-specific genetic associations have previously been reported. 
Markunas et al.
54
 identified association between the SLC9A9 gene and hyperactive/impulsive Conners 
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scores. Lasky-Su et al.
55
 found association between two variants within the dopamine receptor 4 gene 
(DRD4) and ADHD symptoms which was driven by the inattentive symptoms only. In a previous 
paper, using the IMAGE sample, Lasky-Su et al.
10
 investigated domain-specific genetic associations 
using GWAS and reported nominal associations for variants within candidate genes included here. 
Also, in healthy twins, hyperactive/impulsive symptoms have been associated to variants within the 
dopamine pathway
56
. Further, although the neurite outgrowth network has not yet been linked to 
hyperactivity or impulsivity symptoms, it showed overrepresentation in the top results of a GWAS 
study studying motor coordination problems in ADHD
57
 and some neurite outgrowth genes studied 
here, in particular NOS1
58,59
 and CTNNA2
60
, have been associated to impulsivity.  
One possible explanation of lack of association with inattention may be related to a higher degree of  
phenotypic heterogeneity compared to hyperactivity/impulsivity. Therefore, the current sample might 
not have enough power to detect genetic effects. However, as both symptom domains are highly 
heritable (hyperactive/impulsive 88%, inattentive 79%)
61
 and standard deviations are similar (Table 1), 
different phenotypic heterogeneity is not expected. Alternatively genetic mechanisms other than those 
studied here might be involved in the inattention domain.  
The current study analyzed symptom count and symptom severity. Both are part of the 
hyperactive/impulsive domain, however, there is only moderate to small correlation between them. 
Symptom counts have been created through a semi-structured diagnostic interview in combination 
with few items from ADHD rating scales, whereas the symptom severity measures were rated by 
parents or teachers. Therefore we expect them to capture different aspects of the disorder. 
It should be noted that the selected pathways were associated with parental but not with teacher-rated 
hyperactivity/impulsivity. Discrepancies between raters have been observed previously
62-64
, with 
correlations between mother and teacher ratings ranging from .23 to .49
65,66
 and significant differences 
in mean scores
62
. Low correlation values suggest them to capture different aspects of the disorder. 
Linkage analysis for parent-rated and teacher-rated Conners scores also showed rater-specific 
quantitative trait loci
67
. Informant differences can be attributed to several factors, like different 
standards and biases in reporting and scoring the symptoms
63
, or setting-specific behavior observed 
only by one rater
68
. Teacher ratings might be more prone to measurement error, as teachers need to 
divide their attention over multiple children and observe each individual for a limited amount of time 
while performing specific school-related activities. Parents might have more opportunities to observe 
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their child in multiple daily life settings, but can be biased depending on having another child with 
similar behavior or not.  
Our findings should be viewed in light of certain strengths and limitations. An important strength is the 
combination  of multiple genetic variants in a well-characterized ADHD sample accounting for small 
effect sizes and genetic heterogeneity in ADHD.  A limitation is that our sample shows reduced power 
to find associations explaining 1% or less of the variance 
(http://pngu.mgh.harvard.edu/~purcell/gpc/qtlassoc.html) therefore replication in an independent 
sample is necessary. We were unable to define the direction of the effects, or whether directions were 
different for the different genes/pathways studied, which we acknowledge to be a limitation.  
For pathway and gene selection we took a conservative approach, only including genes selected 
using a well-established database or literature. Pathway selection remains difficult as the currently 
available databases are far from complete, therefore we feel they should be used as not more than a 
starting point for pathway analyses. Therefore interesting genes might have been missed. As we only 
included the most promising candidate pathways for ADHD, we might have missed others as new 
candidates are still emerging
50
.   
Given our case-only design, our results should be seen as moderating individual symptoms within the 
disorder, but not necessarily contributing to ADHD susceptibility. To investigate if these pathways 
increase the susceptibility to ADHD a case-control study should be performed. Also, it would be 
interesting to validate the current analysis in samples with an equal gender distribution, adult ADHD 
samples and population-based samples.  
In conclusion, our results support the hypothesis that genes of the dopamine/noradrenaline and 
serotonin neurotransmitter pathways as well as neurite outgrowth genes are involved in ADHD 
through the hyperactive/impulsive component but not the inattentive one. The current study shows that 
pathway-based association analyses in combination with more homogeneous phenotyping may 
overcome power problems in association testing by taking into account allelic heterogeneity. 
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Tables 
Table 1. Demographic characteristics of the studied individuals. 
 Value N 
Mean years of age (SD) 10.83 (2.78) 930 
% male 87 930 
Median symptom count hyperactivity (SD) 8 (1.27) 871 
Median  symptom count inattentiveness (SD) 8 (1.04) 871 
Median Conners’ parent hyperactive/impulsive (SD) 80 (10.15) 930 
Median Conners’ teacher hyperactive/impulsive (SD) 69.5 (12.16) 916 
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Table 2. Selection of genes. 
Genes  dopamine/noradrenaline pathway Genes serotonin pathway Genes neurite outgrowth 
ADCY1 ADRA1D DRD5 PPP1R10 PPP2CA PPP2R5C PTS
a
 DDC
a
 HTR3D SLC18A1
a
 ADAMTS17 EMP2 MAP1B PPM1H 
ADCY10 ADRA2A GCH1
a
 PPP1R11 PPP2CB PPP2R5D QDPR
a
 GCH1
a
 HTR3E SLC18A2
a
 ASTN2 FAM190A MBOAT1 RORA 
ADCY2 ADRA2B IL4I1 PPP1R12A PPP2R1A PPP2R5E SLC18A1
a
 HTR1A HTR4 SLC18A3
a
 ATP2C2 FHIT MEIS2 SLCO3A1 
ADCY3 ADRA2C MAOA
ab
 PPP1R14A PPP2R1B PRKACA SLC18A2
a
 HTR1B HTR5A SLC6A4 BMPR1B FLNC MMP24 SPOCK3 
ADCY4 ADRB1 MAOB
ab
 PPP1R14B PPP2R2A PRKACB SLC18A3
a
 HTR1D HTR6 SMOX
a
 CDH13 GPC6 MOBP SUPT3H 
ADCY5 CALY NCS1 PPP1R14C PPP2R2B PRKACG SLC6A2 HTR1E HTR7 SPR
a
 CDH23 HK1 MYT1L TLL2 
ADCY6 COMT PCBD1
ab
 PPP1R14D PPP2R2C PRKAG1 SLC6A3 HTR2A IL4I1
a
 TPH1 CREB5 HKDC1 NCKAP5 UGT1A9 
ADCY7 DDC
a
 PPM1J PPP1R1B PPP2R3A PRKAG2 SMOX
a
 HTR2B MAOA
ab
 TPH2 CSMD2 ITGA11 NEDD4L UNC5B 
ADCY8 DRD1 PPM1L PPP1R3A PPP2R3B
b
 PRKAR1A SPR
a
 HTR2C
b
 MAOB
ab
 
 
CTNNA2 KCNIP4 NOS1 ZNF423 
ADCY9 DRD2 PPP1CA PPP1R3C PPP2R4 PRKAR1B
b 
TH HTR3A PCBD1
a
 
 
DNM1 KCP NRXN1 
 
ADRA1A DRD3 PPP1CB PPP1R3D PPP2R5A PRKAR2A 
 
HTR3B PTS
a
 
 
DUSP1 LRP1B NUCB1 
 
ADRA1B DRD4 PPP1CC PPP1R7 PPP2R5B PRKAR2B 
 
HTR3C QDPR
a
 
 
DYNC2H1 MAN2A2 NXPH1 
 
a
 present in dopamine/noradrenaline and in serotonin pathways 
b
 no SNPs for analysis 
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Table 3. Association results from the combined analysis of symptom counts and combined and 
separate analysis of three genetic pathways with hyperactive/impulsive (HI) symptom severity 
measured with the parent-rated Conners Scale (n=930). 
 
N 
SNPs 
IA symptom 
counts 
HI symptom 
counts 
HI symptom 
severity p-value 
Combined analysis 5,179 0.73 0.007 0.0018 
Dopamine/noradrenaline 
pathway 
1,163
a 
- - 0.0004 
Serotonin pathway 407
a
 - - 0.0149 
Neurite outgrowth genes 3,860
 
- - 0.0452 
a
 251 SNPs were present in the serotonin pathway as well as in the dopamine/noradrenaline pathway.  
 
Table 4. Correlation analyses between the studied phenotypes. Correlation coefficients are shown 
with corresponding p-values in brackets. 
  
Symptom 
count 
hyperactivity/ 
impulsivity 
Symptom 
counts 
inattentiveness 
Conners parent 
hyperactivity/ 
impulsivity 
Symptom counts inattentiveness .182 (<.001) 
 
 
Conners parent 
hyperactivity/impulsivity 
.254 (<.001)        .087 (.008)  
Conners teacher 
hyperactivity/impulsivity 
.386 (<.001)        .111 (.001) .238 (<.001) 
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Figure legends 
Figure 1 shows the different steps in our analysis. Analysis started by separating the inattentive and 
hyperactive/impulsive symptom counts. As hyperactive/impulsive symptoms showed association, we 
extended the analysis by investigating hyperactive/impulsive symptom severity using Conners’ scores.  
At step 2 post-hoc analysis were performed to investigate the pathways separately.  
